{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:32:28Z","timestamp":1760783548943},"reference-count":13,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.pupt.2012.05.008","type":"journal-article","created":{"date-parts":[[2012,5,29]],"date-time":"2012-05-29T21:50:22Z","timestamp":1338328222000},"page":"293-302","source":"Crossref","is-referenced-by-count":5,"title":["Characteristics of AZD9708, a novel, selective \u03b22-adrenoceptor agonist with rapid onset and long duration of action"],"prefix":"10.1016","volume":"25","author":[{"given":"D.J.","family":"Nicholls","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Cadogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.P.","family":"Austin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.W.","family":"Paine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Gardiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Bonnert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2012.05.008_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1476-5381.2011.01216.x","article-title":"Beta(2) -adrenoceptor agonists: current and future direction","volume":"163","author":"Cazzola","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pupt.2012.05.008_bib2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/1465-9921-11-149","article-title":"Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents","author":"Tashkin","year":"2010","journal-title":"BMC Respir Res"},{"key":"10.1016\/j.pupt.2012.05.008_bib3","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1124\/jpet.105.098251","article-title":"In\u00a0vitro and in\u00a0vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1Hquinolin-2-one (Indacaterol), a novel inhaled Beta-2 adrenoceptor agonist with a 24-h duration of action","volume":"317","author":"Battram","year":"2006","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.pupt.2012.05.008_bib4","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/00002018-200427100-00001","article-title":"A\u00a0benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease","volume":"27","author":"Sovani","year":"2004","journal-title":"Drug Saf"},{"key":"10.1016\/j.pupt.2012.05.008_bib5","series-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2010 update)","author":"GOLD","year":"2011"},{"key":"10.1016\/j.pupt.2012.05.008_bib6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1476-5381.1993.tb13799.x","article-title":"Estimation of partial agonist affinity by interaction with a full agonist: a direct operational model-fitting approach","volume":"110","author":"Leff","year":"1993","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pupt.2012.05.008_bib7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1378\/chest.102.2.535","article-title":"Rapid onset of action of inhaled formoterol in asthmatic patients","volume":"102","author":"Wegener","year":"1992","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2012.05.008_bib8","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0954-6111(98)90348-1","article-title":"Onset and duration of action of single doses of formoterol inhaled via Turbuhaler","volume":"92","author":"Ringdal","year":"1998","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2012.05.008_bib9","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1476-5381.1993.tb13856.x","article-title":"Salmeterol, a long-acting beta 2-adrenoceptor agonist mediating cyclic AMP accumulation in a neuronal cell line","volume":"110","author":"McCrea","year":"1993","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pupt.2012.05.008_bib10","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1183\/09031936.97.10112489","article-title":"Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency","volume":"10","author":"Palmqvist","year":"1997","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2012.05.008_bib11","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1159\/000029427","article-title":"Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action","volume":"66","author":"Celik","year":"1999","journal-title":"Respiration"},{"key":"10.1016\/j.pupt.2012.05.008_bib12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0014-2999(94)90392-1","article-title":"Formoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterol","volume":"251","author":"Nials","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pupt.2012.05.008_bib13","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1183\/09031936.96.09081684","article-title":"Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action","volume":"9","author":"van Noord","year":"1996","journal-title":"Eur Respir J"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553912000727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553912000727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T04:24:24Z","timestamp":1542947064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553912000727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S1094553912000727"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2012.05.008","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}